{
  "name" : "dacemirror.sci-hub.se_journal-article_54ccfd6a6fd0f6a318811a7467a2670f_jiang2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Persistent luminescent multifunctional drug delivery nano- platform based on persistent luminescent nanomaterial ZnGa2O4:Cr,Sn for imaging-guided cancer chemotherapy",
    "authors" : [ "Wenjing Jiang", "Lin Huang", "Fan Mo", "Yingying Zhong", "Liangjun Xu" ],
    "emails" : [ "fengfu@fzu.edu.cn" ],
    "sections" : [ {
      "heading" : null,
      "text" : "This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.\nAccepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.\nYou can find more information about Accepted Manuscripts in the author guidelines.\nPlease note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.\nAccepted Manuscript\nrsc.li/materials-b\nJournal of Materials Chemistry B Materials for biology and medicine www.rsc.org/MaterialsB\nISSN 2050-750X\nPAPER Guoping Chen et al. Regulating the stemness of mesenchymal stem cells by tuning micropattern features\nVolume 4 Number 1 7 January 2016 Pages 1–178\nJournal of Materials Chemistry B Materials for biology and medicine\nView Article Online View Journal\nThis article can be cited before page numbers have been issued, to do this please use: W. Jiang, L.\nHuang, F. Mo, Y. Zhong, L. Xu and F. Fu, J. Mater. Chem. B, 2019, DOI: 10.1039/C9TB00109C."
    }, {
      "heading" : "Journal Name",
      "text" : "ARTICLE\nThis journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 1\nPlease do not adjust margins\nPlease do not adjust margins\na. Key laboratory for analytical science of food safety and biology of MOE, Fujian Provincial Key Lab of Analysis and Detection for Food Safety, College of Chemistry, Fuzhou University, Fuzhou, Fujian 350116, China. Fax/Tel: +86-591-22866135; *Email: fengfu@fzu.edu.cn b. College of Life Sciences, Fujian Agriculture and Forest University, Fuzhou, Fujian 350002, China † Footnotes relating to the title and/or authors should appear here. Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x\nReceived 00th January 20xx, Accepted 00th January 20xx\nDOI: 10.1039/x0xx00000x\nwww.rsc.org/\nPersistent luminescent multifunctional drug delivery nanoplatform based on persistent luminescent nanomaterial ZnGa2O4:Cr3+,Sn4+ for imaging-guided cancer chemotherapy\nWenjing Jiang,a,b Lin Huang a, Fan Moa, Yingying Zhonga, Liangjun Xua, and FengFu Fu* a\nA novel tumor-targeting and release-controllable drug delivery nano-platform with persistent luminescence was\nconstructed for imaging-guided cancer chemotherapy. The persistent luminescent drug delivery nano-platform employed persistent luminescent nanoparticles, ZnGa2O4:Cr3+,Sn4+ (ZGCS), to realize repeatable luminescence-imaging of cell or tissue with high signal-to-noise ratio, mesoporous silica (MS) coated on ZGCS surface to load drug, and hyaluronic acid (HA) to act as gate keeper and targeting moiety. The proposed nano-platform can be repeatedly excited to produce persistent luminescence under red light (550 nm) irradiation to realize repeatable luminescence-imaging of cell or tissue without in situ excitation, and simultaneously possesses excellent tumor-targeting ability to CD-44 over-expressing cancer cells and controllable drug release with hyaluronic acidase (Hyal-1) response. By using the nano-platform, we have successfully delivered non-fluorescent chemotherapeutic drug, paclitaxel (Ptx), into human breast adenocarcinoma cells (MCF-7 cells) with a loading capacity of 0.187 mg/mg and Hyal-1 responsive controllable-release, and simultaneously monitored the distribution of nano-platform and the release of Ptx in target cells by luminescence-imaging. The combination of excellent persistent luminescence feature, tumor-targeting ability and controllable drug release makes the nano-platform a promising nano-platform for imaging-guided cancer chemotherapy, which will greatly enhance the chemotherapeutic efficiency of cancer and reduce the side effects of chemotherapy."
    }, {
      "heading" : "1. Introduction",
      "text" : "With the development of nano-medicine in cancer diagnosis and therapy, studies of nanomaterials-based drug delivery have attracted increasing attention since nanomaterials-based drug delivery can improve drug solubility and cellular uptake, realize targeted delivery and controllable release of drug, and thus enhance cancer therapeutic effect.1-3 So far, many nanomaterials have been used to fabricate smart drug delivery nano-platform. However, most smart drug delivery nanoplatforms previously reported are based on non-luminescent nanomaterials, which make the monitoring of drug release and the imaging-guided chemotherapy impossible when they were used to load drugs without fluorescence.4-8 Introduction of fluorescent probe into drug delivery nano-platform will enable us to trace the drug delivery nano-platform via fluorescent imaging. Thus, the fluorescent feature combining with the\npassive/active tumor-targeting performance will offer drug delivery nano-platform with the ability of recognizing the tumor sites, monitoring the distribution of nano-platform in cells or tissue and evaluating the drug-releasing process, and thus realizing imaging-guided cancer therapy. Therefore, the integration of luminescent probe and chemotherapeutic agents into a single nano-carrier is of great significance for exploring the diseases occurrence, improving the therapeutic accuracy and minimizing the side effects of drug.9,10\nIn recent years, some functional nanoparticles such as quantum dots (QDs) and up-conversion nanoparticles (UCNPs) have been tentatively used to fabricate fluorescence-imaging drug delivery system.11-13 However, most of these fluorescent nano-materials have limited tissue penetration depth and are susceptible to photobleaching or optical quenching,11,14 and thus cannot be used to repeatedly monitor the distribution of nano-platform and the drug-releasing from drug delivery nano-platform in cells or tissue. In addition, the conventional fluorescent nano-materials need to work under in situ excitation, which inevitably suffers from background interference of tissue auto-fluorescence and light scattering, and therefore had poor signal-to-noise ratio (SNR).15 Persistent luminescence (PL) is an optical phenomenon of continuous luminescence, which is caused by the sustained release of radiant energy stored in materials within a certain time.16 In comparison with conventional fluorescent nano-materials, the\nPage 1 of 9 Journal of Materials Chemistry B\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n2 7\nM ar\nch 2\n01 9.\nD ow\nnl oa\nde d\non 3\n/2 8/\n20 19\n1 :4\n8: 19\nA M\n.\nView Article Online DOI: 10.1039/C9TB00109C"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\npersistent luminescent nano-materials (PLM) can still emit luminescence after the excitation was stopped since the excited electrons can be captured and stored in some energy traps and gradually released at room temperature.17-20 Thus, using PLM for luminescence-imaging or luminescence analysis can prominently eliminate the interference of tissue background fluorescence and light scattering, and give a much higher SNR. Therefore, the application of PLM in the fabrication of intelligent drug delivery nano-platform has attracted increasing attention in recent years. Especially, some persistent luminescent nano-materials can repeatedly produce persistent luminescence via repeated visible or near-infrared (NIR) light irradiation.21,22 This provided a promising approach for realizing luminescence-imaging or deep tissue-penetrable luminescence-imaging with high sensitivity without in situ excitation.23-25 So far, several persistent luminescent nanomaterials, such as ZnGa1.995Cr0.005O4Li persistent luminescent nanophosphors, ZnGa2O4Cr0.004 NIR persistent luminescent nanoparticles and Zn2.94Ga1.96Ge2O10:Cr3+,Pr3+ persistent luminescent nanoparticles, have been reported and tentatively used for optical imaging of tissues in vivo due to their extraordinary luminescence performance, deep tissue penetrability and high SNR.25-27 However, many challenges still exist for integrating persistent luminescent bio-imaging and drug delivery into a single nano-platform. Therefore, it is of great significance to explore the potential application of PLM in the fabrication of luminescence-imaging drug delivery nanoplatform.28-31 The introduction of PLM in drug delivery nanoplatform will give the luminescence-imaging function to the nano-platform, and thus enable us to monitor the nanoplatform’s position and drug release process when the nanoplatform was used to deliver non-fluorescent drug. In general, the optical properties of PLM was influenced by many factors, such as its chemical components, nanocrystal structure and particle size. In the design and fabrication of PLM-based drug delivery system, it is crucial to balance the luminescence performance and particle size. Additionally, the modification of PLM to achieve tumor-targeting ability and avoiding the interference of loaded drugs on the luminescence property are also serious challenges for the construction of luminescenceimaging drug delivery system.17 Herein, we prepared ZnGa2O4:Cr3+,Sn4+ (ZGCS) persistent luminescent nano-material, and fabricated a novel tumor-targeting intelligent drug delivery nano-platform by assembling mesoporous silica (MS) shell on ZGCS surface (ZGCS@MS) for loading drug and modifying hyaluronic acid (HA) to ZGCS@MS (ZGCS@MS/HA) for recognizing target cancer cell as well as controlling the release of drug. The proposed ZGCS@MS/HA drug delivery nano-platform can be repeatedly excited to produce persistent luminescence under UV and LED red light irradiation, and thus can simultaneously realize repeatable luminescence-imaging, targeted drug delivery and controlled release of drug. The success of this study is expected to provide a novel luminescence-imaging drug delivery nano-platform for imaging-guided cancer chemotherapy."
    }, {
      "heading" : "2. Experimental section",
      "text" : ""
    }, {
      "heading" : "2.1. Preparation of persistent luminescent nanoparticle",
      "text" : "ZnGa2O4:Cr3+,Sn4+. The persistent luminescent nanoparticle, ZnGa2O4:Cr3+,Sn4+ (ZGCS), was synthesized according to the modified method reported previously.32 Firstly, 4 mmol of Ga(NO3)3, 2 mmol of Zn(NO3)2, 0.004 mmol of Cr(NO3)3, 0.008 mmol of SnCl4, and 3 mmol of polyvinylpyrrolidone-K30 (PVP-K30) were dissolved in 40 mL deionized water, and the mixture was vigorously stirred for 1 h. Subsequently, the pH of mixture was adjusted to 11 with NaOH solution, and the whole was kept in stirring for 2 h. The mixture was then transferred to a hydrothermal reaction kettle and allowed to react at 200 °C for 18 h. After that, the obtained white precipitate was separated by centrifugation and washed with ethanol and deionized water for three times respectively, and then dried in vacuum at 60 °C for 12 h to obtain precursor ZGCS nanoparticles (p-ZGSC). Secondly, 0.1 g of p-ZGSC, 0.2 mL of TEOS and 3.0 mL of ammonia were mixed in 50 mL of ethanol, and then was stirred at room temperature for 4 h to coat silica shell on p-ZGSC surface to form pZGSC@SiO2 nanoparticle. After centrifugation, p-ZGSC@SiO2 was alternately washed for 3 times with deionized water and ethanol, and then dried at 60 °C for 12 h. Following that, the pZGSC@SiO2 was sintered at 900 °C for 4 h, and then naturally cooled to room temperature. Then, 10 mL NaOH solution (2 M) was added and the whole was stirred for 12 h to etch and remove SiO2 coating on the p-ZGSC@SiO2 surface. Finally, the as prepared nanoparticles were separated by centrifugation and washed for 3 times with deionized water and ethanol respectively, and dried at 60 °C for 12 h in vacuum to obtain the ZGCS persistent luminescent nanoparticle. 2.2. Preparation of persistent luminescent tumor-targeting and release-controllable drug delivery nano-platform. Firstly, 4 mg of the as prepared ZGCS nanoparticles were dispersed in a solution containing 9.5 mL of deionized water, 0.1 mL of 0.1 M NaOH and 0.4 mL of 0.2 M hexadecyltrimethylammonium bromide (CTAB), and the whole was stirred for 10min. Then, a total of 90 μL 20% TEOS solution was added (added three times with each time of 30 μL and an interval of 30 min), and the whole was kept in stirring at room temperature for 24 h. Subsequently, 20 μL of 0.1 M (3- aminopropyl) triethoxysilane (APTES) solution was dropwise added to the mixture and the whole was stirred for another 24 h. Then, the obtained mesoporous silica (MS) coated ZGCS nanoparticles (ZGCS@MS), which has a core-shell structure, were collected by centrifugation at 10000 g for 30 min, and washed with 5 times of methanol and ethanol to remove the CTAB template. Finally, the prepared ZGCS@MS was ultrasonically dispersed in 1 mL of deionized water for next use. To load paclitaxel (Ptx) on ZGCS@MS, 0.5 mg of above prepared ZGCS@MS was mixed with 2 mL of paclitaxel solution (0.05 mg/mL) at room temperature, and the whole was stirred for 12 h to obtain Ptx-loaded ZGCS@MS (ZGCS@MS/Ptx). After\ncentrifugation to remove the free Ptx, the prepared ZGCS@MS/Ptx was re-dispersed in 5 mL deionized water, and then 1.0 mg of hyaluronic acid (HA) was added. The whole was\nPage 2 of 9Journal of Materials Chemistry B\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n2 7\nM ar\nch 2\n01 9.\nD ow\nnl oa\nde d\non 3\n/2 8/\n20 19\n1 :4\n8: 19\nA M\n.\nView Article Online DOI: 10.1039/C9TB00109C"
    }, {
      "heading" : "Journal Name ARTICLE",
      "text" : "This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3\nPlease do not adjust margins\nPlease do not adjust margins\nstirred for 24 h to coat HA on the surface of ZGCS@MS/Ptx via electrostatic adsorption to obtain persistent luminescent tumor-targeting and release-controllable drug delivery nanoplatform (ZGCS@MS/Ptx/HA). Finally, the prepared ZGCS@MS/Ptx/HA was collected by removing free HA with centrifugation. 2.3. Paclitaxel loading and release behavior investigation. In order to investigate the drug loading capacity of ZGCS@MS nano-carrier, 0.2 mg of ZGCS@MS dispersion was mixed with Ptx solution with various mass ratios (5:1, 8:1, 10:1), and the whole was stirred for 12 h. The free Ptx was removed by centrifugation, and the concentration of free Ptx in the solution before and after loading was determined by high performance liquid chromatography (HPLC) with UV detector at 227 nm. The drug loading capacity and loading efficiency was calculated according to the Ptx standard curve and the following formula:\nPtx loading capacity = (\uD835\uDC5A0 −\uD835\uDC5A1) \uD835\uDC5A⁄ Ptx loading efficiency = (\uD835\uDC5A0 −\uD835\uDC5A1) \uD835\uDC5A0⁄\nwhere m0 represents the Ptx initial mass, m1 is the free Ptx mass found in supernatant, m is the mass of ZGCS@MS.\nThe release behavior of Ptx in the ZGCS@MS/Ptx/HA persistent luminescent drug delivery nano-platform was studied by dialysis experiments. In detail, 2 mg of ZGCS@MS/Ptx/HA and hyaluronidase (Hyal-1, 50 U/mL) were mixed in dialysis tubes and dialyzed in 50 mL of PBS buffer solution with different pH (7.4 or 5.0) under constant stirring in three replicates. The control group was not supplemented with Hyal-1 and other conditions were the same as above. About 400 μL of dialysate was separately taken out at specific time points (0, 1, 2, 4, 6, 8, 12, 24, 36, and 48h) for the quantification of released Ptx, and an equal amount of blank PBS was added to maintain the total volume of the solution. The release amount of Ptx was determined by HPLC with UV detector at 227 nm. 2.4. Cellular uptake assessment. The uptake of persistent luminescent ZGCS@MS/Ptx/HA nanoplatform in human breast adenocarcinoma cell line (MCF-7, target cells) and mouse embryonic fibroblast cells (NIH3T3, control cells) was studied by confocal laser scanning microscopy (CLSM). Prior to CLSM imaging analysis, MCF-7 and NIH3T3 cells were respectively plated on cell culture dishes at a density of 5.0 × 105 cells/well, and cultured at 37 °C for 12 h. After washing three times with PBS buffer, 1.5 µM of ZGCS@MS/Ptx/HA (Ptx equivalent) in 500 µL complete culture medium was added and further incubated for 6 h. The residual drug and necrotic cells were removed by washing with PBS buffer, and the nuclei were stained by adding 500 μL of Hoechst 33342 (10 μg/mL) for 20min. Finally, the cellular uptake of ZGCS@MS/Ptx/HA was assessed by CLSM analysis.\nFor flow cytometry analysis, 1.5 µM of ZGCS@MS/Ptx/HA (Ptx equivalent) in 500μL complete culture medium was added into each cell species (MCF-7 and NIH3T3) at the density of 1.0×106 cells/mL. After incubating for 6 h, the cells were washed twice with PBS buffer to remove the residual nanoparticles and dead cells. The cells were subsequently incubated with trypsin (1mL, 0.05%) for 1 min, washed by PBS\nbuffer once again and suspended in PBS buffer (1mL). Finally, the obtained cells were analyzed with a BD C6 Plus flow cytometer. 2.5. Cytotoxicity evaluation. To evaluate the cytotoxicity, MCF-7 (target cells) and NIH3T3 (control cells) were respectively cultured in 96-well plates at a density of 1.0×104 cells/well in triplicate, and cultured for 12 h to completely adhere the cells. After washed twice with PBS buffer, then 500 μL of cell culture medium containing various concentrations (0.5, 1.0, 1.5, 1.8, and 2.0 μM, Ptx equivalent) of ZGCS@MS/HA, ZGCS@MS/Ptx/HA or Taxol (Ptx in Cremophor EL and ethanol, v/v = 1:1) was added, and the whole was incubated for 12 h. Finally, the treated cells were washed with PBS buffer and stained with 100 μL of CCK-8 for 45 min. The cell viability was evaluated via measuring the absorbance at 450 nm by a microplate reader."
    }, {
      "heading" : "3. Results and discussion",
      "text" : ""
    }, {
      "heading" : "3.1. Preparation and characterization of persistent luminescent drug delivery nano-platform.",
      "text" : "As shown in Scheme 1, in our strategy, the persistent luminescent nanoparticle, ZnGa2O4:Cr3+,Sn4+ (ZGCS), was used as signal source for repeatable luminescence-imaging, MS coated around ZGCS was used to encapsulate anticarcinogen namely Ptx, and HA was used as targeting moiety for recognizing target cancer cells and simultaneously as gate keeper for controlling Ptx release.\nScheme 1. (A) Schematic illustration of preparing tumor-targeting and releasecontrollable persistent luminescent drug delivery nano-platform (ZGCS@MS/Ptx/HA); (B) The application of ZGCS@MS/Ptx/HA for luminescence imaging-guided cancer chemotherapy.\nA\nTEOS Ptx\nZGCS ZGCS@MS ZGCS@MS/Ptx\nHA\nHyal-1\nPtx release\nUV/LED\nPL\nUV/LED\nPL PL\nUV/LED\nUV/LED\nPL\nZGCS@MS/Ptx/HA\nUV/LED\nPL\nB\nChemotherapy LED\nPage 3 of 9 Journal of Materials Chemistry B\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n2 7\nM ar\nch 2\n01 9.\nD ow\nnl oa\nde d\non 3\n/2 8/\n20 19\n1 :4\n8: 19\nA M\n.\nView Article Online DOI: 10.1039/C9TB00109C"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "4 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nTo confirm whether the ZGCS@MS/Ptx/HA persistent luminescent nano-platform has been fabricated as we expected. Firstly, the size and morphology of ZGCS and ZGCS@MS nanoparticles were characterized with transmission electron microscopy (TEM). As shown in Figure 1-a, the prepared persistent luminescent nanoparticles, ZGCS, possess well dispersity with a uniform size about 15 nm. After MS was coated on the surface of ZGCS nanoparticles, it can be clearly observed (Figure 1-b and 1-c) that the formed ZGCS@MS nano-composites exhibited a distinct core-shell structure with wormhole-like mesopores in the shell and a bigger size of ~100 nm. To confirm the fabrication of ZGCS@MS nano-composites, the energy dispersive X-ray spectroscopy (EDX) analysis including element mapping was used to investigate the components and the element’s distribution of ZGCS@MS nano-composite. As results shown in Figure 1-d, it can be obviously observed that ZGCS@MS contained Zn, Ga, Cr, Sn and Si elements. The EDX mapping analysis (Figure 2) revealed that elements of Cr, Ga, Sn, and Zn seem to locate in the core of ZGCS@MS nano-composite and Si mainly distributes in the shell of the ZGCS@MS nano-composite. All above results forcefully verified that the ZGCS@MS nano-composites with a ZGCS metal core and MS shell were successfully prepared, like Scheme 1.\nFigure 1. TEM images of ZGCS nanoparticles (a), ZGCS@MS nanoparticles (b), and ZGCS@MS nanoparticles magnified (c). The EDX spectrum of ZGCS@MS nanocomposites (d).\nThe chemical components and surface electronic state of elements can be accurately reflected by X-ray photoelectron spectroscopy (XPS). Therefore, we further investigated the components of the prepared persistent luminescent ZGCS@MS nano-composites with XPS. In addition to the binding energy of C 1s peak at 285 eV and that of O 1s peak at 530 eV, we can also observe the 2p peak of Zn at 1043 eV and 1020 eV, the 2p peak of Cr at 586 eV, the 2p peak of Ga at\n1116 eV, the 3d peak of Ga at 19 eV and 2p peak of Si at 104.6 eV, as shown in Figure 3 and Figure S1 (see Electronic Supplementary Information, ESI). Although the content of Sn is too low to be detected, the main constituent elements (Zn, Ga, Cr and Si) determined above are sufficient to confirm that the ZGCS@MS persistent luminescent nano-composites were successfully fabricated.\nFigure 2. The EDX mapping images of ZGCS@MS nano-composites.\nFigure 3. The XPS spectra of ZGCS@MS nano-composites.\nThe Zeta-potential analysis suggested the successful fabrication of persistent luminescent ZGCS@MS/HA nanocomposites too. Like Figure S2 (see ESI), the persistent luminescent nanoparticle, ZGCS, is negatively charged due to the NaOH-etched SiO2 layer after sintering. The positive charge exhibited by ZGCS@MS confirmed that the amino-modified MS shell has been successfully coated on the surface of ZGCS nanoparticles. Subsequently, HA was adsorbed on the surface of ZGCS@MS by electrostatic adsorption to give ZGCS@MS/HA an obvious negative charge, which made the ZGCS@MS/HA nano-composites keep good stability in physiological environment. 3.2. Persistent luminescence performance investigation.\nPage 4 of 9Journal of Materials Chemistry B\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n2 7\nM ar\nch 2\n01 9.\nD ow\nnl oa\nde d\non 3\n/2 8/\n20 19\n1 :4\n8: 19\nA M\n.\nView Article Online DOI: 10.1039/C9TB00109C"
    }, {
      "heading" : "Journal Name ARTICLE",
      "text" : "This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5\nPlease do not adjust margins\nPlease do not adjust margins\nDuring the preparation of the persistent luminescent drug delivery nano-platform, the luminescence properties of ZGCS, ZGCS@MS and ZGCS@MS/HA have been investigated respectively. From the fluorescence excitation and emission spectra in Figure 4-a, we can observed that all above 3 nanocomposites have the same fluorescence emission spectra with a max emission at 695 nm and a second emission at 705 nm under 252 nm excitation, which should be mainly attributed to the spin forbidden of 2E→4A2 transition and its phonon sidebands.25,31 The emission band longer than 650 nm has relatively low absorption and scattering property in the normal tissue, which will lead to deeper tissue penetration ability, and thus providing a possibility for biological tissue imaging. Furthermore, all ZGCS, ZGCS@MS and ZGCS@MS/HA have two broad excitation bands located at 252 nm and 400-600 nm respectively with a fixed emission wavelength of 695 nm, which are respectively ascribed to the charge transfer absorption of O2--Ga3+ in ZnGa2O4 and the 4A2→4T1 (4P), 4A2→4T1 (4F), 4A2→4T2 (4F) transitions of Cr3+ in the octahedral crystal field.32,33 It is worth noting that ZGCS possesses the best luminescence performance in comparison with ZGCS@MS and ZGCS@MS/HA. It can be explained as that the coating layer of MS or HA weakens the absorption of ZGCS so that the luminescence intensity is slightly reduced. However, ZGCS@MS and ZGCS@MS/HA still exhibit similar and good luminescence performance.\nIn addition, the persistent luminescence properties of above 3 nano-composites have also been studied. The persistent luminescence decay at 695nm was monitored after 5 min irradiation by a handheld UV lamp at the wavelength of 254 nm. The persistent luminescence decay curves in Figure 4- b revealed that the prepared ZGCS, ZGCS@MS and ZGCS@MS/HA nanoparticles or nano-composites have remarkable persistent luminescence performance with a satisfied intensity within 20 min. Namely, ZGCS, ZGCS@MS and ZGCS@MS/HA nano-composites can still continuously emit intensive luminescence for 20 min after the excitation was stopped. Since ZGCS@MS/HA has a wide excitation band in the visible region, we further investigated the persistent luminescence performance of ZGCS@MS/HA after accepting repeated irradiation with a LED lamp (550 nm) for 10 min. The result in Figure 4-c demonstrated that the luminescence decay tendency and degree nearly keep consistent after repeated exposure under LED lamp, implying that the persistent luminescence of ZGCS@MS/HA has good reproducibility without photobleaching or quenching. Therefore, ZGCS@MS/HA not only is a tumor-targeting and releasecontrollable drug delivery nano-platform but also is an ideal persistent luminescence probe, which can be used to deliver anticarcinogen to target cells with controllable-release and simultaneously realize repeatable luminescence-imaging of cells or tissue with high SNR via repeated LED irradiation. Thus, the ZGCS@MS/HA provided a promising approach for imagingguided targeted therapy in clinical therapy of cancer.\nFigure 4. (a) Excitation and emission spectra of ZGCS, ZGCS@MS and ZGCS@MS/HA nanoparticles. (b) Persistent luminescence decay curve of ZGCS, ZGCS@MS and ZGCS@MS/HA nanoparticles after 5 min of 254 nm UV light irradiation. (c) Persistent luminescence decay curve of ZGCS@MS/HA nanoparticle after 10 min LED repeated irradiation (550nm)."
    }, {
      "heading" : "3.3. Fluorescence-imaging, drug loading and drug release behavior.",
      "text" : "The accurate cancer therapy can be realized by virtue of tumor-targeting intelligent drug delivery system. However, as we mentioned above, most intelligent drug delivery nanoplatforms previously reported are based on non-luminescent nano-materials, which make the monitoring of drug release and the imaging-guided chemotherapy impossible when they were used to load drugs without fluorescence.4-8 Although the\nloading of fluorescent drug can well make up for this deficiency, it still requires to work under in situ excitation, which inevitably suffers from background interference of\nPage 5 of 9 Journal of Materials Chemistry B\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n2 7\nM ar\nch 2\n01 9.\nD ow\nnl oa\nde d\non 3\n/2 8/\n20 19\n1 :4\n8: 19\nA M\n.\nView Article Online DOI: 10.1039/C9TB00109C"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "6 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\ntissue auto-fluorescence and light scattering, and finally resulting in poor SNR.15 The application of persistent luminescent nano-materials in the fabrication of intelligent drug delivery nano-platform can offer the ability of recognizing tumor sites, monitoring the distribution of nano-platform in cells or tissue, evaluating the drug-releasing process, and realizing imaging-guided cancer therapy under repeated visible or near-infrared (NIR) light irradiation with high sensitivity. Paclitaxel (Ptx) is an excellent natural chemotherapeutic agent that has been widely used in the treatment of diseases such as breast cancer, ovarian cancer and lung cancer.34,35 Therefore, we herein employed ZGCS@MS/HA to load non-fluorescent Ptx to investigate the fluorescence-imaging, drug loading and drug release behavior of ZGCS@MS/HA persistent luminescent nano-platform.\nIt was well-known that HA is a natural substance that supports cell growth and tissue composition, which has specific affinity for CD-44 receptors. It has been reported that HA-modified drug delivery systems can selectively recognize and accumulate around CD-44 over-expressing cancer cells and further be internalized into cells via HA receptor-mediated endocytosis,36-38 reducing the intake of drugs by normal cells. In this study, HA is not only employed as a capping agent to prevent Ptx from leaking in advance, but also endows the drug delivery nano-platform with good active targeting performance.\nFigure 5. (a) Confocal fluorescence microscopy images of cells incubated with ZGCS@MS/Ptx/HA. Data was obtained after irradiated cells for 5 min with LED (550 nm); (b) Flow cytometry histograms of cells incubated with ZGCS@MS/Ptx/HA.\nAs stated, ZGCS@MS/HA exhibits excellent persistent luminescence properties under the excitation of ultraviolet (254 nm) or LED (550 nm), which suggests great promise as a nano-probe for diagnostic luminescence-imaging. After loading the non-fluorescent drug of Ptx, the cellular uptake of ZGCS@MS/Ptx/HA can be monitored by the generated luminescence of the nano-platform. Herein, CD-44 overexpressed human breast adenocarcinoma cell line (MCF-7, target cells) and mouse embryonic fibroblast cells (NIH3T3, control cells) were selected to evaluate the targeted cellular uptake of ZGCS@MS/Ptx/HA. As shown in Figure 5-a, brighter red fluorescence derived from ZGCS can be observed in MCF-7 cells compared to that of NIH3T3 cells. The CLSM imaging analysis (Figure 5-a) and the flow cytometry analysis (Figure 5- b) confirmed that the ZGCS@MS/Ptx/HA nano-platform possesses excellent persistent luminescence property for luminescence-imaging as well as remarkable active targeting ability for entering and accumulating in target MCF-7 cells, which helps to improve the therapeutic efficacy of target tissues and minimize the side effects on normal cells. After 1 h, re-irradiated ZGCS@MS/Ptx/HA using LED (550 nm) for 5 min, the bright red luminescence derived from ZGCS can also be observed in MCF-7 cells (see Figure S3 in ESI), indicating that the persistent luminescent nano-platform ZGCS@MS/Ptx/HA holds great potential for achieving repeatable imaging-guided cancer therapy under LED light irradiation.\nAdditionally, the maximum drug loading capacity and loading efficiency of ZGCS@MS was determined to be 0.187 mg/mg and 93.5% respectively for Ptx, respectively. It was reported that HA can be decomposed by the lysosomal hyaluronidase (Hyal-1) in the tumor microenvironment to trigger drug release,36 and pH values drop further inside cells in the endosome/lysosome and cytosol of cancer cells (pH 4.5−6.0).39 For investigating the drug release behavior in response to Hyal-1, ZGCS@MS/Ptx/HA with or without adding Hyal-1 was respectively dialyzed under different pH conditions (pH 5.0 and 7.4). As illustrated in Figure S4 (see ESI), the cumulative Ptx release of ZGCS@MS/Ptx/HA without Hyal-1 kept less than 10% within 48h, while significantly enhanced drug release was observed after adding Hyal-1, indicating that HA coating exhibits effective capping effect to prevent Ptx premature leakage and can rapidly response to Hyal-1 to trigger Ptx release. Additionally, it can be found that the Ptx release rate at pH 5.0 was significantly enhanced in comparison with that at pH 7.4. The cumulative release of Ptx under pH 5.0 was as high as 91% at 48 h, whereas only a 67% cumulative release was obtained under pH 7.4. This is mainly due to the fact that Hyal-1 is more active in weak acidic environment so that it can thoroughly decompose HA to realize more efficient drug release. 3.4. Cytotoxicity and targeted therapeutic efficiency.\nPtx is an effective therapeutic agent and has been widely used for breast cancer chemotherapy. By means of drug delivery nano-platform, Ptx can be accurately targeted delivered into cancer cells. The increased intake of drug in cancer cells can reduce the side effects of drugs on normal\nPage 6 of 9Journal of Materials Chemistry B\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n2 7\nM ar\nch 2\n01 9.\nD ow\nnl oa\nde d\non 3\n/2 8/\n20 19\n1 :4\n8: 19\nA M\n.\nView Article Online DOI: 10.1039/C9TB00109C"
    }, {
      "heading" : "Journal Name ARTICLE",
      "text" : "This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 7\nPlease do not adjust margins\nPlease do not adjust margins\ntissues, effectively improving the therapeutic effect. The cytotoxicity of ZGCS@MS/HA, ZGCS@MS/Ptx/HA and Taxol on MCF-7 (target cells) and NIH3T3 (control cells) was investigated at various concentrations (Ptx equivalent) in this study. The results in Figure 6 revealed that both MCF-7 and NIH3T3 cells maintained high cell viability even at high concentration of ZGCS@MS/HA, implying that ZGCS@MS/HA persistent luminescent nano-platform possesses excellent biocompatibility, which is critical for biomedical application. Meanwhile, Taxol generated similar and concentrationdependent cytotoxicity for both cell lines. In the case of ZGCS@MS/Ptx/HA, it was found that the cell viability also gradually decreased with the increasing of Ptx concentration. The survival rate of MCF-7 cells (target cells) was reduced to 16% at 2 μM (Ptx equivalent) of ZGCS@MS/Ptx/HA, which was much lower than the 64% of NIH3T3 cells (control cells). The more serious cell damage caused by the drug to MCF-7 verified that ZGCS@MS/Ptx/HA nano-platform has remarkable active tumor-targeted ability, which make it can specifically recognize and accumulate in target MCF-7 cells, and the HA monolayer coating on ZGCS@MS/Ptx/HA surface was rapidly decomposed by intracellular Hyal-1 to explosively release Ptx in target MCF7 cells. The increase of drug internalization by MCF-7 target cells significantly enhanced cytotoxicity and thus obtained a satisfactory targeted therapeutic effect.\nFigure 6. Cell viability of MCF-7 cells (a) and NIH3T3 cells (b), which treated with various concentrations (Ptx equivalent) of ZGCS@MS/HA, ZGCS@MS/Ptx/HA and Taxol.\nAll above experimental results verified that the proposed ZGCS@MS/HA persistent luminescent nano-carrier not only possesses excellent persistent luminescence but also has excellent tumor-targeting and release-controllable features. It can be repeatedly excited to produce persistent luminescence under LED red light (550 nm) irradiation to realize repeatable luminescence-imaging, and simultaneously realize targeted drug delivery and controlled release. The success of ZGCS@MS/HA persistent luminescent nano-carrier promised a promising nano-platform for imaging-guided cancer chemotherapy."
    }, {
      "heading" : "4. Conclusions",
      "text" : "In summary, we herein fabricated a novel tumor-targeting and release-controllable drug delivery nano-platform (ZGCS@MS/HA) for imaging-guided cancer chemotherapy by using persistent luminescent nanoparticles ZGCS as cores, mesoporous silica (MS) coated on ZGCS surface as carrier and hyaluronic acid (HA) as gate keeper as well as targeting moiety. The ZGCS@MS/HA nano-platform has excellent persistent luminescence, which makes it can be repeatedly excited to produce persistent luminescence under LED red light (550 nm) irradiation to realize repeatable luminescence-imaging of cell or tissue without in situ excitation. Simultaneously it possesses excellent tumor-targeting ability and controllable drug release with Hyal-1 response. By using ZGCS@MS/HA nano-platform, we have successfully delivered non-fluorescent chemotherapeutic drug, Ptx, into target MCF-7 cells with a loading capacity of 0.187 mg/mg, and simultaneously realized the controllable-release of drug in cells and the luminescenceimaging of target cells, which can be used to monitor the distribution of ZGCS@MS/Ptx/HA in cells. The combination of excellent persistent luminescence feature, tumor-targeting ability and controllable drug release makes ZGCS@MS/HA a promising nano-platform for imaging-guided cancer chemotherapy, and thus enhance the chemotherapeutic efficiency of cancer and reduce the side effects of chemotherapy."
    }, {
      "heading" : "Conflicts of interest",
      "text" : "There are no conflicts to declare."
    }, {
      "heading" : "Acknowledgements",
      "text" : "The authors gratefully acknowledge National Natural Science Foundation of China (21677034), The National Key Research and Development Program of China (2017YFC1600500), and The Education Department of Fujian Province of China (JAT170206) for financial support."
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\n2 N. Li, L. Zhao, L. Qi, Z. Li, Y. Luan, Prog. Polym. Sci., 2016, 58, 1. 3 Z. Liu, J. Robinson, S. Tabakman, K. Yang, H. Dai, Mater. Today, 2011, 14, 316. 4 J. Liu, L. Cui, D. Losic, Acta Biomater., 2013, 9, 9243. 5 T. Sun, Y. Zhang, B. Pang, D. Hyun, M. Yang, Y. Xia, Angew.\nChem., Int. Ed., 2014, 53, 12320. 6 F. S. Majedi, M. M. Hasani-Sadrabadi, J. J. VanDersarl, N.\nMokarram, S. Hojjati-Emami, E. Dashtimoghadam, S. Bonakdar, M. A. Shokrgozar, A. Bertsch, P. Renaud, Adv. Funct. Mater., 2014, 24, 432. 7 G. Gonçalves, M. Vila, M.-T. Portolés, M. Vallet-Regi, J. Gracio, P. A. Marques, Adv. Healthc. Mater., 2013, 2, 1072. 8 L. Shao, R. Zhang, J. Lu, C. Zhao, X. Deng, Y. Wu, ACS Appl. Mater. Inter., 2017, 9, 1226. 9 H. Ding, F. Wu, Theranostics, 2012, 2, 1037. 10 W. Jiang, F. Mo, Y. Lin, X. Wang, L. Xu, F.-F. Fu, J. Mater.\nChem. B, 2018, 6, 4360. 11 X. Michalet, F. F. Pinaud, L. A. Bentolila, J. M. Tsay, S. Doose,\nJ. J. Li, G. Sundaresan, S. S. Wu, et al., Science, 2005, 307, 538. 12 J. Zhou, Z. Liu, F. Li, Chem. Soc. Rev., 2012, 41, 1323. 13 D. K. Chatterjee, M. K. Gnanasammandhan, Y. Zhang, Small,\n2010, 6, 2781. 14 C. H. F. Wenk, F. Ponce, S. Guillermet, C. Tenaud, D. Boturyn,\nP. Dumy, D. Watrelot-Virieux, C. Carozzo, V. Josserand, J.-L. Coll, Cancer Lett., 2013, 334, 188. 15 A. Hellebust, R. Richards-Kortum, Nanomedicine, 2012, 7, 429. 16 Y. Li, M .Gecevicius, J. Qiu, Chem. Soc. Rev. 2016, 45, 2090. 17 J. Wang, Q. Ma, Y. Wang, H. Shen, Q. Yuan, Nanoscale, 2017,\n9, 6204. 18 T. Lécuyer, E. Teston, G. Ramirez-Garcia, T. Maldiney, B.\nViana, J. Seguin, N. Mignet, D. Scherman, C. Richard, Theranostics, 2016, 6, 2488. 19 L. C. V. Rodrigues, H. F. Brito, J. Hölsä, R. Stefani, M. C. F. C. Felinto, M. Lastusaari, T. Laamanen, L. A. O. Nunes, J. Phys. Chem. C, 2012, 116, 11232. 20 B. Qu, B. Zhang, L. Wang, R. Zhou, X. Zeng, L. Li, ACS Appl. Mater. Inter., 2016, 8, 5439. 21 J. Shi, X. Sun, J. Li, H. Man, J. Shen, Y. Yu, H. Zhang, Biomaterials, 2015, 37, 260. 22 L. Chen, S. Sun, Y. Wang, C. Yang, S. Wu, X. Yan, ACS Appl. Mater. Inter., 2016, 8, 32667. 23 A. Abdukayum, J. T. Chen, Q. Zhao, X. P. Yan, J. Am. Chem. Soc., 2013, 135, 14125. 24 R. Abdurahman, C. X. Yang, X. P. Yan, Chem. Commun., 2016, 52, 13303. 25 Y. Wang, C. X. Yang, X. P. Yan, Nanoscale, 2017, 9, 9049. 26 T. Maldiney, A. Bessière, J. Seguin, E. Teston, S. K. Sharma, B.\nViana, A. J. J. Bos, P. Dorenbos, M. Bessodes, D. Gourier, D. Scherman, C. Richad, Nat. Mater., 2014, 13, 418. 27 Z. Li, Y. Zhang, X. Wu, L. Huang, D. Li, W. Fan, G. Han, J. Am. Chem. Soc., 2015, 137, 5304. 28 Y. J. Li, C. X. Yang, X. P. Yan, Anal. Chem., 2018, 90, 4188. 29 T. Maldiney, B. Ballet, M. Bessodes, D. Scherman, C. Richard,\nNanoscale, 2014, 6, 13970. 30 S. K. Sun, H. F. Wang, X. P. Yan, Accounts Chem. Res., 2018,\n51, 1131. 31 J. M. Liu, D. D. Zhang, G. Z. Fang, S. Wang, Biomaterials,\n2018, 165, 39. 32 R. Zou, J. Huang, J. Shi, L. Huang, X. Zhang, K. L. Wong, H.\nZhang, D. Jin, J. Wang, Q. Su, Nano Res., 2017, 10, 2070. 33 A. Bessière, S. Jacquart, K. Priolkar, A. Lecointre, B. Viana, D.\nGourier, Opt. Express, 2011, 19, 10131. 34 I. Rivkin, K. Cohen, J. Koffler, D. Melikhov, D. Peer, R.\nMargalit, Biomaterials, 2010, 31, 7106. 35 Y. Zhong, K. Goltsche, L. Cheng, F. Xie, F. Meng, C. Deng, Z.\nZhong, R. Haag, Biomaterials, 2016, 84, 250.\n36 Z. W. Chen, Z. H. Li, Y. H. Lin, M. L. Yin, J. S. Ren, X. G. Qu, Chem.-Eur. J., 2013, 19, 1778. 37 W. J. Jiang, F. Mo, X. in, L. Chen, L. J. Xu, L. Q. Guo, F.-F. Fu, Adv. Mater. Inter., 2017, 4, 1700425. 38 H. Y. Yoon, H. Koo, K. Y. Choi, S. J. Lee, K. Kim, I. C. Kwon, J. F. Leary, K. Park, S. H. Yuk, J. H. Park, K. Choi, Biomaterials, 2012, 33, 3980. 39 X. X. Yao, Z. F. Tian, J. X. Liu, Y. F. Zhu, N. Hanagata, Langmuir, 2017, 33, 591.\nPage 8 of 9Journal of Materials Chemistry B\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n2 7\nM ar\nch 2\n01 9.\nD ow\nnl oa\nde d\non 3\n/2 8/\n20 19\n1 :4\n8: 19\nA M\n.\nView Article Online DOI: 10.1039/C9TB00109C\nTable Of Content\nTEOS Ptx\nZGCS ZGCS@MS ZGCS@MS/Ptx\nHA\nHyal-1\nUV/LED\nPL\nUV/LED\nPL PL\nUV/LED\nUV/LED\nPL ZGCS@MS/Ptx/HA\nChemotherapy LED Cellular uptake\nA novel tumor-targeting and release-controllable drug delivery nano-platform with persistent luminescence was constructed for imaging-guided cancer chemotherapy by employing persistent luminescent nanoparticles, ZnGa2O4:Cr3+,Sn4+ (ZGCS), to realize repeatable luminescence-imaging of cell or tissue with high signal-to-noise ratio, mesoporous silica (MS) coated on ZGCS surface to load drug, and hyaluronic acid (HA) to act as gate keeper and targeting moiety.\nPage 9 of 9 Journal of Materials Chemistry B\nJo ur\nna lo\nfM at\ner ia\nls C\nhe m\nis tr\ny B\nA cc\nep te\nd M\nan us\ncr ip\nt\nPu bl\nis he\nd on\n2 7\nM ar\nch 2\n01 9.\nD ow\nnl oa\nde d\non 3\n/2 8/\n20 19\n1 :4\n8: 19\nA M\n.\nView Article Online DOI: 10.1039/C9TB00109C"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the ethical guidelines, outlined in our author and reviewer resource centre, still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. Accepted Manuscript",
    "creator" : "Aspose Ltd."
  }
}